-
- 抗原 See all PDCD1LG2 抗体
- PDCD1LG2 (Programmed Cell Death 1 Ligand 2 (PDCD1LG2))
-
适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This PDCD1LG2 antibody is un-conjugated
-
应用范围
- Flow Cytometry (FACS)
- 品牌
- BD Pharmingen™
- 纯化方法
- The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
- 过滤
- 0.2 μm filtered
- 内毒素水平
- Endotoxin level is ≤ 0.01 EU/μg (≤ 0.001 ng/μg) of protein as determined by the LAL assay.
- 克隆位点
- MIH18
- 亚型
- IgG1 kappa
- Top Product
- Discover our top product PDCD1LG2 Primary Antibody
-
-
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1.0 mg/mL
- 缓冲液
- No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2μm sterile filtered.
- 储存液
- Azide free
- 储存条件
- 4 °C
- 储存方法
- Store undiluted at 4°C. This preparation contains no preservatives, thus it should be handled under aseptic conditions.
-
-
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 11, Issue 8, pp. 2947-53, (2005) (PubMed).
: "Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 170, Issue 2, pp. 711-8, (2003) (PubMed).
: "Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 170, Issue 3, pp. 1257-66, (2003) (PubMed).
: "PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2." in: European journal of immunology, Vol. 32, Issue 3, pp. 634-43, (2002) (PubMed).
: "PD-L2 is a second ligand for PD-1 and inhibits T cell activation." in: Nature immunology, Vol. 2, Issue 3, pp. 261-8, (2001) (PubMed).
: "
-
Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 11, Issue 8, pp. 2947-53, (2005) (PubMed).
-
- 抗原
- PDCD1LG2 (Programmed Cell Death 1 Ligand 2 (PDCD1LG2))
- 别名
- CD273 (PDCD1LG2 产品)
- 背景
-
The MIH18 monoclonal antibody specifically binds to CD273, the Programmed Death Ligand 2 (PD-L2). PD-L1 and PD-L2 are newly discovered members of the B7 family that are the ligands for the Programmed Death 1 (PD-1) receptor. They are expressed on immature dendritic cells and mature dendritic cells. PD-L1 is expressed on antigen-presenting cells, including IFN-g-stimulated monocytes and activated human and mouse dendritic cells. Monoclonal antibodies that block PD- 1 and PD-L2 on dendritic cells result in enhanced T cell proliferation and cytokine production. PD-L2, also called B7-DC, is expressed on placental trophoblasts, myocardial endothelium and medullary thymic epithelial cells. Studies show overlapping functions of PD-L1 and PD-L2 and indicate an important role for the PD-L:PD-1 pathway in regulating T cell responses.
Synonyms: PDCD1LG2, PDCD1 ligand 2, PDCD1L2, PD-1 ligand 2, PD-L2, PDL2, B7-DC, Btdc
-